3386 related items for PubMed ID: 17313557
1. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[Abstract] [Full Text] [Related]
2. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[Abstract] [Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB.
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[Abstract] [Full Text] [Related]
4. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[Abstract] [Full Text] [Related]
5. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, Gabriele A, Bonifazi F, Salvucci M, Tura S, Baccarani M.
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[Abstract] [Full Text] [Related]
6. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[Abstract] [Full Text] [Related]
7. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A, Fruchart C, Bastit D, Boulet D, Moncondult M, Piguet H, Tilly H.
Cancer; 1996 Jun 01; 77(11):2302-7. PubMed ID: 8635099
[Abstract] [Full Text] [Related]
8. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M, Ballerini F, Canepa L, Gobbi M.
Oncol Rep; 2005 Oct 01; 14(4):933-40. PubMed ID: 16142354
[Abstract] [Full Text] [Related]
9. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, del Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, San Miguel JF.
Bone Marrow Transplant; 1997 Sep 01; 20(6):451-8. PubMed ID: 9313877
[Abstract] [Full Text] [Related]
10. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, Feng FY.
Ai Zheng; 2005 Apr 01; 24(4):465-9. PubMed ID: 15820071
[Abstract] [Full Text] [Related]
11. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A, Martino R, Perea G, Ribera JM, López-Guillermo A, Guardia R, Escoda L, Altés A, Sierra J, Montserrat E.
Haematologica; 2002 Oct 01; 87(10):1028-35. PubMed ID: 12368156
[Abstract] [Full Text] [Related]
12. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS.
Bone Marrow Transplant; 1993 Oct 01; 12(4):337-45. PubMed ID: 7506091
[Abstract] [Full Text] [Related]
13. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
Bone Marrow Transplant; 1996 Feb 01; 17(2):149-55. PubMed ID: 8640159
[Abstract] [Full Text] [Related]
14. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.
Eur J Haematol Suppl; 2001 Jul 01; 64():28-32. PubMed ID: 11486397
[Abstract] [Full Text] [Related]
15. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F.
Haematologica; 1999 Nov 01; 84(11):1007-11. PubMed ID: 10553161
[Abstract] [Full Text] [Related]
16. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Lee SM, Ryder WD, Clemons MJ, Morgenstern GR, Chang J, Scarffe JH, Radford JA.
Bone Marrow Transplant; 1999 Aug 01; 24(3):271-7. PubMed ID: 10455365
[Abstract] [Full Text] [Related]
17. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
Bone Marrow Transplant; 2000 Aug 01; 26(4):383-8. PubMed ID: 10982284
[Abstract] [Full Text] [Related]
18. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, Gooley T, Holmberg L, Lilleby K, Clift R, Zuckerman N, Klarnet J, Weaver C, Chauncey T, Bensinger WI.
Biol Blood Marrow Transplant; 1997 Nov 01; 3(5):261-6. PubMed ID: 9450921
[Abstract] [Full Text] [Related]
19. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
Zinzani PL, Barbieri E, Visani G, Gherlinzoni F, Perini F, Neri S, Bendandi M, Ammendolia I, Salvucci M, Babini L.
Haematologica; 1994 Nov 01; 79(6):508-12. PubMed ID: 7534744
[Abstract] [Full Text] [Related]
20. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M, Leonard J, Shuster MW, Kaufman TP.
Eur J Haematol Suppl; 2001 Jul 01; 64():41-5. PubMed ID: 11486401
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
